Therapeutic Asset Ratings
7,041 results matching 1 filter
129,999 assets · 8,711 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Gilteritinib
Acute Myeloid Leukemia, FLT3 Internal Tandem Duplication
The First Affiliated Hospital of Soochow University
P3
BB
(69)
Hetrombopag
Thrombocytopenia
Sun Yat-sen University
P3
BB
(69)
HR20013
Chemotherapy-Induced Toxicity
Fujian Shengdi Pharmaceutical Co., Ltd.
P3
BB
(69)
Imatinib
B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2)
The University of Hong Kong
P3
BB
(69)
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
Colon Carcinoma
IFOM ETS - The AIRC Institute of Molecular Oncology
P3
BB
(69)
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
Recurrent Colon Carcinoma
IFOM ETS - The AIRC Institute of Molecular Oncology
P3
BB
(69)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Lymphoplasmacytic Lymphoma
Memorial Sloan Kettering Cancer Center
P3
BB
(69)
Inno-206
Hodgkin'S Lymphoma, Mixed Cellularity
National Cancer Institute (NCI)
P3
BB
(69)
Inno-206
Nodular Sclerosis Classical Hodgkin Lymphoma
National Cancer Institute (NCI)
P3
BB
(69)
Inno-206
Hodgkin'S Lymphoma, Lymphocytic Depletion
National Cancer Institute (NCI)
P3
BB
(69)
Inno-206
Childhood Lymphocyte Depletion Hodgkin Lymphoma
National Cancer Institute (NCI)
P3
BB
(69)
Inno-206
Fallopian Tube Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
P3
BB
(69)
Inno-206
Fallopian Tube Serous Adenocarcinoma
National Cancer Institute (NCI)
P3
BB
(69)
Inno-206
Leukemia
Dana-Farber Cancer Institute
P3
BB
(69)
Inno-206
Lymphoma
Beth Israel Deaconess Medical Center
P3
BB
(69)
Inno-206
Ovarian Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.
P3
BB
(69)
Inno-206
Ovarian Clear Cell Adenocarcinoma
National Cancer Institute (NCI)
P3
BB
(69)
Inno-206
Ovarian Endometrioid Adenocarcinoma
National Cancer Institute (NCI)
P3
BB
(69)
Ipilimumab
Cutaneous Melanoma
Amsterdam UMC, location VUmc
P3
BB
(69)
Ipilimumab
Clinical Stage IV Cutaneous Melanoma AJCC v8
Amsterdam UMC, location VUmc
P3
BB
(69)
Irinotecan
Liver Metastases
Kamya Sankar
P3
BB
(69)
Irinotecan
Metastatic Malignant Neoplasm
Incyte Corporation
P3
BB
(69)
Irinotecan
Primary Peritoneal Carcinoma
Tianjin Medical University Cancer Institute and Hospital
P3
BB
(69)
LABETALOL
Essential Hypertension
ProMedica Health System
P3
BB
(69)
LABETALOL
Mechanical Thrombectomy
ProMedica Health System
P3
BB
(69)
Showing 726 to 750 of 7,041 assets
Previous
Page 30 of 282
Next